(Q28329436)

Europe PubMed Central

PubMed publication ID

797502

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A797502

29 July 2022

G. M. Shaw

series ordinal

2

1 reference

Europe PubMed Central

PubMed publication ID

797502

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A797502

Clinical Pharmacokinetics

29 July 2022

language of work or name

English

0 references

publication date

1976

0 references

published in

0 references

volume

1

0 references

issue

5

0 references

page(s)

313-38

0 references

1 reference

12 December 2020

Effect of intravenously administered probenecid in humans on the levels of 5-hydroxyindoleacetic acid, homovanillic acid and 3-methoxy-4-hydroxy-phenylglycol in cerebrospinal fluid

1 reference

12 December 2020

Free and conjugated dopamine in plasma during levodopa therapy.

1 reference

12 December 2020

Inhibition of DOPA accumulation by rat brain at critical L-DOPA circulating concentrations.

1 reference

12 December 2020

Central monoamine metabolism in man. Effect of putative dopamine receptor agonists and antagonists

1 reference

12 December 2020

L-3,4-dihydroxyphenylalanine metabolism by the gut in vitro

1 reference

12 December 2020

1 reference

12 December 2020

Origins of catecholamine metabolites in monkey cerebrospinal fluid

1 reference

12 December 2020

Plasma DOPA response to levodopa administration in man: Effects of a peripheral decarboxylase inhibitor

1 reference

12 December 2020

Metabolic interactions of pyridoxine, levodopa, and carbidopa in Parkinson's disease

1 reference

12 December 2020

Variations in the "on-off" phenomenon.

1 reference

12 December 2020

Metabolic fate of l-[14C] DOPA in cerebrospinal fluid and blood plasma of humans.

1 reference

12 December 2020

Plasma concentration of levodopa in patients with Parkinson's disease

1 reference

12 December 2020

Dopaminergic supersensitivity in the striatum

1 reference

12 December 2020

Cerebrospinal fluid flow and iodide 131 transport in the spinal subarachnoid space.

1 reference

12 December 2020

1 reference

12 December 2020

1 reference

12 December 2020

1 reference

12 December 2020

The clinical physiology of side effects in long-term L-DOPA therapy.

1 reference

12 December 2020

An analysis of six patients with Parkinson's disease who have been unresponsive to L-dopa therapy

1 reference

12 December 2020

Catecholamine Metabolism During Oral Administration of Levodopa

1 reference

12 December 2020

Effect of chronic amphetamine exposure on stereotyped behavior: implications for pathogenesis of l-dopa-induced dyskinesias

1 reference

12 December 2020

Patterns of clinical response and plasma dopa levels in Parkinson's disease

1 reference

12 December 2020

Comparison of dopa decarboxylase inhibitor (carbidopa) combined with levodopa and levodopa alone on the cardiovascular system of patients with Parkinson's disease

1 reference

12 December 2020

Appraisal of long-term levodopa treatment of parkinsonism with special reference to therapy limiting factors.

1 reference

12 December 2020

Modification of levodopa effect by systemic decarboxylase inhibition

1 reference

12 December 2020

Pyridoxine reversal of L-dopa effects in Parkinsonism.

1 reference

12 December 2020

Drug Therapy of Parkinsonism

1 reference

12 December 2020

1 reference

12 December 2020

1 reference

12 December 2020

Five years' treatment of Parkinson's disease with levodopa. Therapeutic results and survival of 100 patients

1 reference

12 December 2020

Absorption and Metabolism of Levodopa

1 reference

12 December 2020

Some studies of the effects of chlorpromazine, reserpine and dihydroxyphenylalanine on the concentrations of homovanillic acid, 3,4-dihydroxyphenylacetic acid and 5-hydroxyindol-3-ylacetic acid in ventricular cerebrospinal fluid of the dog using th

1 reference

12 December 2020

The pharmacokinetic basis of therapeutics with special reference to drugs used in neurology

1 reference

12 December 2020

Brain catecholamines and their metabolites in Parkinsonian patients. Treatment with levodopa alone or combined with a decarboxylase inhibitor

1 reference

12 December 2020

Behavioral effects of l-Dopa in schizophrenic patients

1 reference

12 December 2020

Levodopa: a review of its pharmacological properties and therapeutic use with particular reference to Parkinsonism

1 reference

12 December 2020

1 reference

12 December 2020

The cerebrospinal fluid homovanillic acid concentration in patients with Parkinsonism treated with L-dopa

1 reference

12 December 2020

"On-Off" Phenomena Related to High Plasma Levodopa

1 reference

12 December 2020

Absence of Response to Levodopa in Parkinson's Disease

1 reference

12 December 2020

On the origin of homovanillic acid in the cerebrospinal fluid.

1 reference

12 December 2020

DOPA and amino acid levels in plasma and cerebrospinal fluid of patients with parkinson's disease before and during treatment with L-dOPA

1 reference

12 December 2020

Acute overdose with levodopa. Clinical and biochemical consequences

1 reference

12 December 2020

Acid monoamine metabolites in the cerebrospinal fluid of patients with Parkinson's disease.

1 reference

12 December 2020

Effect of apomorphine and pimozide on synthesis and turnover of labelled catecholamines in mouse brain

1 reference

12 December 2020

1 reference

12 December 2020

Peripheral aromaticl-amino acids decarboxylase inhibitor in parkinsonism. II. Effect on metabolism ofl-2-14C-dopa

1 reference

12 December 2020

L-dopa treatment failure: explanation and correction

1 reference

12 December 2020

Predictive Value of the Probenecid Test for the Effect of L-Dopa Therapy in Parkinson's Disease

1 reference

12 December 2020

Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system

1 reference

12 December 2020

Comparison of dopa decarboxylase inhibitor (carbidopa) combined with levodopa and levodopa alone in Parkinson's disease

1 reference

12 December 2020

The clinical pharmacology of levodopa

1 reference

12 December 2020

Predicting response to levodopa.

1 reference

12 December 2020

Effect of ergot drugs on central catecholamine neurons: evidence for a stimulation of central dopamine neurons.

1 reference

12 December 2020

1 reference

12 December 2020

Plasma dopa concentrations and the "on-off" effect after chronic treatment of Parkinson's disease

1 reference

12 December 2020

1 reference

12 December 2020

Drug-Induced Changes of Extracerebral Dopa Metabolism in Man

1 reference

12 December 2020

Effect of amantadine on L-2-14C-dopa metabolism in parkinsonism

1 reference

12 December 2020

Metoclopramide, Gastric Emptying and L-Dopa Absorption

1 reference

12 December 2020

1 reference

12 December 2020

1 reference

12 December 2020

Intestinal decarboxylation of orally administered L-dopa. Influence of pharmacological preparations, dose magnitude, dose sequence and food intake

1 reference

12 December 2020

Observations on patients with Parkinson's disease treated with L-dopa. I. Trial and evaluation of L-dopa therapy

1 reference

12 December 2020

The effect of probenecid on catecholamine metabolites in human cerebrospinal fluid analyzed by mass fragmentography

1 reference

12 December 2020

Letter: Diphasic dyskinesia during levodopa therapy

1 reference

12 December 2020

Plasma concentrations of L-dopa and 3-methoxydopa and improvement in clinical ratings and motor performance in patients with Parkinsonism treated with L-dopa alone or in combination with amantadine

1 reference

12 December 2020

1 reference

12 December 2020

Comparison of benefit from L-dopa in Parkinsonism with increase of amine metabolites in the CSF

1 reference

12 December 2020

1 reference

12 December 2020

Some anomalies in the L-DOPA response: recent biochemical studies.

1 reference

12 December 2020

Pyridoxine and Levodopa in The Treatment of Parkinsonism

1 reference

12 December 2020

Amino acid and dopa levels in plasma and urine from L-dopa-treated patients with Parkinson's disease

1 reference

12 December 2020

Homovanillic acid and 5-hydroxyindoleacetic acid in the cerebrospinal fluid of patients with senile dementia, presenile dementia and parkinsonism

1 reference

12 December 2020

Interactions between levodopa and other drugs: significance in the treatment of Parkinson's disease.

1 reference

12 December 2020

The "on-off" side effect of L-DOPA.

1 reference

12 December 2020

Parkinsons disease and its chemotherapy

1 reference

12 December 2020

L-dopa level in plasma, primary condition for the kinetic effect

1 reference

12 December 2020

Treatment of Parkinson's disease with aporphines. Possible role of growth hormone

1 reference

12 December 2020

1 reference

12 December 2020

The mechanisms of action of L-dopa in Parkinson's disease

1 reference

12 December 2020

1 reference

12 December 2020

CSF homovanillic acid: an index of dopaminergic activity

1 reference

12 December 2020

"On-off" phenomenon with levodopa therapy in Parkinsonism. Clinical and pharmacologic correlations and the effect of intramuscular pyridoxine

1 reference

12 December 2020

Lithium and levodopa in parkinsonism

1 reference

12 December 2020

Human growth hormone response to levodopa. Relation to menopause, depression, and plasma dopa concentration

1 reference

12 December 2020

Cardiovascular effects of levodopa

1 reference

12 December 2020

Changes of blood pressure, pulse and electrolytes following long-term treatment of Parkinsonism using Ro 8-0576 (L-Dopa and decarboxylase inhibitor)

1 reference

12 December 2020

Plasma concentration of levodopa in Parkinsonism before and after inhibition of peripheral decarboxylase

1 reference

12 December 2020

Dihydroxyphenylalanine (DOPA) in plasma during dopa treatment of patients with Parkinson's disease

1 reference

12 December 2020

Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations

1 reference

12 December 2020

Pyridoxine, DOPA, and Parkinsonism

1 reference

12 December 2020

Carbidopa in Parkinson disease and in nausea and vomiting of levodopa

1 reference

12 December 2020

Protein Intake and Treatment of Parkinson's Disease with Levodopa

1 reference

12 December 2020

L-dopa therapy of Parkinson's disease: plasma L-dopa concentration, therapeutic response, and side effects

1 reference

12 December 2020

Individualization of levodopa therapy

1 reference

12 December 2020

Failure of cerebrospinal fluid homovanillic acid to predict levodopa response in Parkinson's disease

1 reference

12 December 2020

1 reference

12 December 2020

On-off response. Clinical and biochemical correlations during oral and intravenous levodopa administration in parkinsonian patients

1 reference

12 December 2020

1 reference

12 December 2020

Levodopa and Schizophrenia

1 reference

12 December 2020

"On-off" effects in patients with Parkinson's disease on chronic levodopa therapy

1 reference

12 December 2020

1 reference

12 December 2020

The treatment of parkinsonism. Current concepts

1 reference

12 December 2020

Efficacy of and possible differences in tolerance to L-dopa tablets with different rates of release of the active substance.

1 reference

12 December 2020

Effects of peripheral aromatic l-amino acids decarboxylase inhibitor on L-[2-14C]-3,4-dihydroxy-phenylalanine metabolism in man

1 reference

12 December 2020

Effect of chronic levodopa treatment on pyridoxine metabolism

1 reference

12 December 2020

Phenolic acid concentrations in the lumbar cerebrospinal fluid of Parkinsonian patients treated with L-dopa

1 reference

12 December 2020

Central Monoamine Metabolism in Parkinson's Disease

1 reference

12 December 2020

Parkinson's disease and amine metabolites in cerebrospinal fluid: implications for L-Dopa therapy

1 reference

12 December 2020

1 reference

12 December 2020

L-dopa and cerebrospinal fluid homovanillic acid in parkinsonism

1 reference

12 December 2020

Value of plasma-dopa determinations in the management of Parkinson's disease

1 reference

12 December 2020

Treatment failures with levodopa in Parkinsonism

1 reference

12 December 2020

Short- and long-term approaches to the "on-off" phenomenon

1 reference

12 December 2020

Levodopa combined with peripheral decarboxylase inhibition in Parkinson's disease

1 reference

12 December 2020

Biochemical investigations in patients with Parkinson's disease treated with L-dopa

1 reference

12 December 2020